August 21, 2014
August 20, 2014
August 19, 2014
World’s First Stem-Cell Drug Approval Achieved in Canada
On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal, its drug for acute graft-versus host disease in children who have failed to respond to steroid treatment. Prochymal is the first stem cell drug to be approved anywhere in the world for a systemic disease.
Graft-versus-host disease, a potentially fatal complication from bone marrow transplant, involves the newly implanted cells attacking the patient’s body. Until now, there have been no approved treatments for the disease. Prochymal is designed to control inflammation and promote tissue regeneration. Since the drug is made up of bone marrow stem cells derived from an adult donor, it circumvents ethical concerns that are raised by the use of stem cells derived from embryos.
The Canadian approval is contingent on Osiris conducting further post-market testing—and it’s anticipated that if the FDA approves the drug when marketing authorization is sought later this year, similar conditions would be imposed.
<span class="advertise"> Advertisement </span>
- FDA Issues Final Guidance on "In Vitro Companion Diagnostic Devices"
- FDA Issues Guidance for Drug & Device Companies’ Social Media Interactions
- Office of Inspector General (OIG) Issues Unfavorable Advisory Opinion to Specialty Pharmacy For Support Service Payments
- CMS Re-Opens Open Payments System
- CMS Finalizes Program Changes for Medicare Advantage and Prescription Drug Benefit Programs - Alert!
- Circuits Split Over Legality of IRS Rule Mandating Tax Credits for Individuals Covered Through Federal Exchanges under the Affordable Care Act